{"id":"W3124917933","doi":"10.1016/j.jtho.2020.11.029","title":"Shifting From a “One Size Fits All” to a Tailored Approach for Immune-Related Adverse Events","year":2021,"lang":"en","type":"letter","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Takeda Canada; Merck Sharp and Dohme; Roche Italia; Daiichi Sankyo Company; Clovis Oncology; Merck KGaA; United Therapeutics Corporation; Celgene; Bayer; Novartis; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Pembrolizumab; Medicine; Nivolumab; Adverse effect; Lung cancer; Internal medicine; Oncology; Scopus; Clinical trial; Docetaxel; Cancer; MEDLINE; Immunotherapy","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001753199,0.0004359777,0.001088699,0.0005105255,0.002274418,0.002433237,0.0009037817,0.01954619,0.007722947],"category_scores_gemma":[0.01689448,0.000319987,0.001085274,0.0003925738,0.001718893,0.002157533,0.0009410967,0.0203759,0.00436844],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002228648,"about_ca_system_score_gemma":0.002855191,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001644528,"about_ca_topic_score_gemma":0.003927915,"domain_scores_codex":[0.9977545,0.000735544,0.0003300567,0.0002328901,0.000598054,0.0003489726],"domain_scores_gemma":[0.9946484,0.002696868,0.0003127515,0.0001680563,0.0008071705,0.001366762],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001609353,0.0001765453,0.003861362,0.0001074183,0.0000555095,0.01003412,0.0001594632,0.0005026738,0.0005805898,0.005146071,0.9396529,0.03956239],"study_design_scores_gemma":[0.0009162248,0.0005274076,0.006549294,0.001209383,0.0001573374,0.03673112,0.001010673,0.00437256,0.001052878,0.06343285,0.883848,0.0001923903],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"editorial","genre_scores_codex":[0.001366021,0.0008714466,0.0003122263,0.9833656,0.009017817,0.00001492334,0.0000333604,0.00003123202,0.004987411],"genre_scores_gemma":[0.0200439,0.001202295,0.0009263401,0.9161712,0.05691687,0.00004213018,0.00004356427,0.00002705073,0.004626729],"genre_candidate":"editorial","genre_consensus":null,"teacher_disagreement_score":0.01954619,"threshold_uncertainty_score":0.02583581,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04296113153062505,"score_gpt":0.3796146406216526,"score_spread":0.3366535090910275,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}